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Background: The ability of b blockers to improve left ventricular function has been demonstrated, but data
on the effects on cardiac remodelling are limited.
Objective: To investigate, using cardiovascular magnetic resonance (CMR), the effects of carvedilol on left
ventricular remodelling in patients with chronic stable heart failure and left ventricular systolic dysfunction
caused by coronary artery disease.
Design: Randomised, double blind, placebo controlled study.
Setting: Chronic stable heart failure.
Patients and intervention: 34 patients with chronic stable heart failure and left ventricular systolic function
taking part in the CHRISTMAS trial (double blind carvedilol v placebo) underwent CMR before
randomisation and after six months of treatment.
Main outcome measure: Left ventricular remodelling at six months.
Results: The carvedilol and placebo groups were well balanced at baseline, with no significant intergroup
differences. Over the study period, there was a significant reduction in end systolic volume index (ESVI)
and end diastolic volume index (EDVI) between the carvedilol and the placebo group (carvedilol 29 v
placebo +3 ml/m2, p = 0.0004; carvedilol 28 v placebo 0 ml/m2, p = 0.05). The ejection fraction
increased significantly between the groups (carvedilol +3% v placebo 22%, p = 0.003).
Conclusions: Treatment of chronic stable heart failure with carvedilol results in significant improvement in
left ventricular volumes and function. These effects might contribute to the benefits of carvedilol on mortality
and morbidity in patients with chronic heart failure.
R
ecent years have seen a notable improvement in both
morbidity and mortality in patients with chronic
heart failure. Much of this benefit is derived from the
use of therapeutic agents, including angiotensin converting
enzyme (ACE) inhibitors and b blockers, which interfere with
neurohormonal pathways that are activated by cardiac
dysfunction. In placebo controlled trials, b blockers have
consistently improved survival, reduced hospital admissions,
and improved symptoms and quality of life.1–5
Much of the benefit of b blockade in patients with heart
failure secondary to left ventricular systolic dysfunction may
result from their ability to improve left ventricular systolic
function, which has been demonstrated in various studies
using echocardiography or nuclear techniques.6–8 Data on
cardiac remodelling, however, are limited. Cardiovascular mag-
netic resonance (CMR) provides an accurate and reprodu-
cible measurement of left ventricular remodelling in small
sample sizes, by assessment of volumes, ejection fraction,
and mass.9 10 We investigated the effects of carvedilol versus
placebo on left ventricular volume, mass, and function using
CMR as a measure of cardiac remodelling in patients with
chronic stable chronic heart failure and left ventricular
systolic dysfunction caused by coronary artery disease. This
was a substudy of the CHRISTMAS trial (carvedilol hiberna-
tion reversible ischaemia trial; marker of success).11 12
METHODS
Patients
Thirty four consecutive patients recruited for the
CHRISTMAS trial from two participating centres were
included in the CMR substudy. Patients were recruited
between 1995 and 1999, and the study began before
publication of the major b blocker outcome trials in chronic
heart failure. The inclusion and exclusion criteria for the
CHRISTMAS trial were as follows:
N chronic stable heart failure (New York Heart Association
functional class I–III) from systolic dysfunction caused by
coronary artery disease
N already receiving optimised chronic heart failure treatment
(including diuretics and an ACE inhibitor if tolerated)
N echocardiographic imaging of sufficient quality for wall
motion analysis.
Patients with atrial fibrillation or severe valvar disease
were excluded, and additional exclusion criteria for the CMR
substudy were the presence of an implanted pacemaker and
claustrophobia.
Study design
Patients underwent the first CMR scan after inclusion in the
CHRISTMAS trial, but before randomisation to carvedilol or
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Abbreviations: CHRISTMAS, carvedilol hibernation reversible
ischaemia trial, marker of success; CMR, cardiovascular magnetic
resonance; COI, cardiac output index; COMET, carvedilol or metoprolol
European trial; EDVI, end diastolic volume index; EF, ejection fraction;
ESVI, end systolic volume index; LVEDV, left ventricular end diastolic
volume; LVESV, left ventricular end systolic volume; LVMI, left ventricular
mass index; LVSVI, left ventricular stroke volume index
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placebo. The follow up scan was done six months after
randomisation, while patients were still on double blind
treatment. Height, weight, and blood pressure were recorded
before scanning, the latter done after 20 minutes of rest in a
sitting position. During each study, heart rate was recorded
continuously and the average heart rate during the scanning
sequence noted.
The CMR substudy was approved by the ethics committees
of both participating centres, and written consent was
obtained.
CMR measurement of remodelling
CMR was done with a Picker Edge 1.5 T scanner (Marconi,
Cleveland, Ohio, USA), using the body coil and ECG
triggering, as previously described.13 In brief, the cardiac
short axis was determined from three scout images of the
left ventricle—the transverse axis, the vertical long axis, and
the breath hold diastolic horizontal long axis. The basal short
axis slice was positioned just forward of the atrioventricular
ring, and all subsequent breath hold cines were acquired in
1 cm steps towards the apex. A breath hold, segmented
gradient echo, fast low angle shot (FLASH) sequence was
used for each of the contiguous short axis slices. Parameters
were as follows: echo time (TE), 3.8 ms; repeat time
(TR) = RR interval; slice thickness, 10 mm; field of view,
356 35 cm; read matrix, 256; phase matrix, 128; frames, 16;
flip angle, 35 ;̊ phase encode group, 6–10. An average of 10
short axis segments was needed to encompass the entire left
ventricle.
Image analysis was carried out on a personal computer
using software developed in-house (CMRtools, Cardio-
vascular Imaging Solutions, London, UK). End diastolic and
end systolic images were chosen as the maximum and
minimum cross sectional areas in each cine. Short axis end
diastolic epicardial and endocardial borders were traced
manually for each slice. From the area within the contours
and the slice thickness, the epicardial volume and endocar-
dial volume (left ventricular end diastolic volume, LVEDV)
were calculated, the difference representing myocardial
volume. Left ventricular mass (LVM) was derived from this
volume by multiplying by the specific density of the
myocardium (1.05 g/cm3).14 End systolic endocardial borders
were also traced, to give left ventricular end systolic volume
(LVESV). The dif-
ference between LVEDV and LVESV represents the left
ventricular stroke volume (SV). Ejection fraction (EF (%))
was calculated as (LVEDV – LVESV)/LVEDV 6 100. Papillary
muscles were included in the mass and excluded from the
volume. All analyses were done off-line in random order,
with investigators blinded to the patient details and previous
results.
Statistical analysis
To control for changes in body mass index over the study
period, EDV, ESV, SV, cardiac output (CO), and LVM were
expressed as an index of total body surface area—EDVI, ESVI,
LVSVI, COI, and LVMI—by dividing each variable by the
patient’s body surface area.15 Unpaired t tests between the
carvedilol and placebo groups were employed at baseline to
detect any initial differences. Differences within the carvedi-
lol and placebo groups over the study period were assessed
using a paired t test. Differences between the carvedilol and
placebo groups over time were examined using an unpaired
t test on the intragroup differences. Results are expressed as
mean (SD), with a probability value of p , 0.05 being
considered significant. Statistical analyses were done with
commercial software (StatView version 4.53; Abacus
Concepts Inc, Berkeley, California, USA). The reproducibility
of CMR in our centre has been published previously and the
interstudy percentage variability is 2.5% for EDV, 3.1% for
Table 1 Comparison of ventricular remodelling and haemodynamic variables at baseline and at the end of the study between







p Value, within group
changes (95% CI)




2) Carvedilol* 139 (46) 131 (46) NS Q 0.001 (3.5 to 12.8) 0.05 (20.3 to14.6)
Placebo* 130 (43) 130 (39) R NS (26 to 7.5)
LVESVI (ml/m
2) Carvedilol 100 (48) 91 (45) NS Q 0.0004 (4.8 to 13.0) 0.0004 (5.9 to18.2)
Placebo 89 (34) 92 (37) R NS (27.8 to 1.7)
LVSVI (ml/m
2) Carvedilol 39 (9) 40 (7) NS R NS (26.8 to 3) NS
Placebo 41 (13) 36 (8) R NS (21.3 to 9.6)
LVEF (%) Carvedilol 31 (13) 34 (13) NS q 0.008 (25 to 20.8 0.003 (28.5 to 21.9)
Placebo 32 (10) 30 (10) R NS (20.6 to 5.2)
LVMI (g/m
2) Carvedilol 77 (23) 77 (18) NS R NS (26.8 to 8) NS
Placebo 91 (24) 89 (29) R NS (25.6 to 10.9)
Heart rate (beats/min) Carvedilol 80 (13) 74 (14) NS R NS (22.2 to 14.0) NS
Placebo 84 (8) 80 (12) R NS (25 to 11)
BP systolic (mm Hg) Carvedilol 121 (18) 116 (13) NS R NS (21.2 to 11) NS
Placebo 127 (20) 121 (14) R NS (22.3 to 15)
BP diastolic (mm Hg) Carvedilol 74 (13) 73 (12) NS R NS (23.0 to 6.7) NS
Placebo 70 (13) 73 (9) R NS (23.0 to 14.6)
BSA (m2) Carvedilol 1.8 (0.1) 2.0 (0.2) NS R NS (20.01 to 0.02) NS
Placebo 1.8 (0.2) 1.8 (0.1) R NS (20.07 to 0.02)
Values are mean (SD).
*Carvedilol group, n = 16; placebo group, n = 13.
BP, blood pressure; BSA, body surface area; LVEDVI, left ventricular end diastolic volume index; LVEF, left ventricular ejection fraction; LVESVI, left ventricular end
systolic volume index; LVMI, left ventricular mass index; LVSVI, left ventricular stroke volume index; R, no effect over time; q, increase over time; Q, decrease
over time.
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ESV, 4.8% for EF, and 3% for LVM.9 The minimum detectable
differences in EDV, ESV, EF, and LVM by CMR for the 16
subjects in the carvedilol group were therefore 2.8 ml, 3.6 ml,
6% (absolute change), and 3.5 g, respectively; for the 13
subjects in the placebo group, the values were 3.2 ml, 4 ml,
6% (absolute change), and 3.8 g.
RESULTS
Thirty four patients were recruited into the CMR study and
underwent a baseline scan. Of these, five did not complete
the study. One patient was withdrawn from the substudy
following a possible drug interaction, one because of
worsening heart failure, one because of sleep apnoea, and
two because of claustrophobia. These patients were therefore
excluded from the analysis. All but one of the patients
recruited were male. Their mean (SD) age was 71 (8.5) years.
Mean EDVI was 135 (44) ml/m
2 (normal 66 (12) ml/m2);
mean ESVI, 95 (42) ml/m
2 (normal 21 (8) g/m2); mean EF,
31 (11)%; and mean LVMI, 83 (24) g/m
2 (normal 87 (24) g/
m2) (normal values are from Lorenz and colleagues 16). Mean
body surface area was 1.84 m2. The groups were well
balanced at baseline, with no significant differences between
them (table 1). The mean dose of carvedilol achieved in the
CMR study patients was 32 (15) mg.
Change over time within each group
In the carvedilol group, the mean EDVI decreased from 139 to
131 ml/m2 (p = 0.001), representing a 5% decrease over the
study period. The ESVI decreased by 9% (from 100 to 91 ml/
m2, p = 0.0004), while ejection fraction increased by 9%
(from 31% to 34%, 3% absolute, p = 0.008). There was no
change in LVSVI, COI, LVMI, or blood pressure. Within the
placebo group there were no significant changes in any of the
remodelling indices over time. The changes are summarised
in fig 1.
Differences between groups over time
Over the study period, the carvedilol group showed a reduc-
tion in ESVI (carvedilol 29 ml/m
2 v placebo +3, p = 0.0004).
There was also a significant difference in EDVI (carvedilol
28 ml/m2 v placebo 0, p = 0.05) and ejection fraction
(carvedilol +3% v placebo 22%, p = 0.003). None of the
other variables differed significantly.
DISCUSSION
The main finding of this study is that over six months’
treatment of chronic stable heart failure, carvedilol resulted
in a significant decrease in left ventricular volumes at both
Figure 1 Change in variables over six months. LVEDVI, left ventricular
end diastolic volume index; LVESVI, left ventricular end systolic volume
index; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass
index. *p , 0.05, p , 0.01 for the comparison of the change in
variable over time between carvedilol and placebo groups.
Table 2 Randomised trials of the effect of b blocker treatment on ejection fraction
Study n
Duration
(months) Treatment 1 EF change* Treatment 2 EF change*
Absolute
difference
Present study 34 6 Carvedilol 8 Placebo 22 10
Metra44 34 4 Carvedilol 10 Placebo 21 11
Olsen1 57 4 Carvedilol 11 Placebo 1 10
Krum23 43 4 Carvedilol 7 Placebo 0 7
MOCHA study24 143 7 Carvedilol 9 Placebo 1 8
PRECISE study25 225 7 Carvedilol 8 Placebo 2 6
Colucci26 185 7 Carvedilol 10 Placebo 3 7
Cohn27 55 7 Carvedilol 9 Placebo 2 7
ANZ study3 358 12 Carvedilol 5 Placebo 0 5
Guazzi28 21 6 Carvedilol 9 Placebo 21 10
DiLenarda29 30 12 Carvedilol 7 Metoprolol 0 7
Metra22 122 14 Carvedilol 11 Metoprolol 7 4
Kukin6 53 6 Carvedilol 6 Metoprolol 5 1
Sanderson30 43 3 Carvedilol 9 Metoprolol 6 3
Engelmeier31 24 12 Metoprolol 6 Placebo 4 2
MDC study32 205 12 Metoprolol 12 Placebo 6 6
Fisher33 50 6 Metoprolol 4 Placebo 0 4
Goldstein34 51 6 Metoprolol 9 Placebo 2 7
RESOLVD study35 419 6 Metoprolol 3 Placebo 1 2
*Absolute percentage change in ejection fraction.
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end systole and end diastole and thereby a reversal of adverse
left ventricular remodelling. In addition, the left ventricular
ejection fraction improved significantly with carvedilol. Left
ventricular volumes and LVEF are strong predictors of all
cause mortality and sudden death,17–19 and a causal relation is
suspected. Despite a reduction in volumes and arterial
pressure, which should have reduced left ventricular wall
stress, no reduction in left ventricular mass was observed.
An improved mass/volume ratio, leading to a reduction in
left ventricular wall stress, could be of benefit either by
reducing the metabolic demands on the left ventricle or by
reducing the potential for arrhythmias. The sample size used
here precludes stratification by dose, but a larger sample and
a longer period of follow up could give additional insights
into the effect of increasing doses of carvedilol and the
duration of treatment on left ventricular remodelling.
Many studies have shown improvement in left ventricular
function with b blockers (table 2), but the mechanism
remains poorly understood. The degree of functional
improvement exerted by different agents, as illustrated by a
meta-analysis of trials of carvedilol and metoprolol, has led to
the suggestion that pharmacological effects other than pure
b1 blockade are responsible.
20 Indeed, carvedilol significantly
reduced mortality compared with metoprolol in the recent
COMET study.21 Investigators have, however, cautioned that
this may simply reflect a lack of equivalence in the b1
blockers used rather than any additional pharmacological
benefits. The exact mechanism of functional improvement
has yet to be determined.21
Despite the wealth of studies on the effect of b blockers on
left ventricular function, there have been few previous
studies of the effect on left ventricular remodelling. Sharpe
and colleagues found a significant reduction in EDV and ESV
with carvedilol treatment over 12 months using cross
sectional echocardiography in a 123 patient substudy of the
Australia/New Zealand heart failure research collaborative
group study.7 36 These patients had heart failure of ischaemic
origin and were already on an ACE inhibitor. Khattar and
colleagues showed a reduction in ESV, but no change in EDV
by cross sectional echocardiography with carvedilol mono-
therapy, and did not find any benefit in ESV when an ACE
inhibitor was added to the carvedilol group.37 There was,
however, a significant reduction in ESV when carvedilol was
added in patients who had received six months of ACE
inhibitor treatment alone. Groenning and colleagues pub-
lished a randomised CMR study showing that metoprolol had
reverse remodelling effects in 41 patients with chronic heart
failure, with a significant reduction in EDVI and ESVI over
six months of treatment.38 More recently, Dubach and
associates used CMR to investigate a placebo controlled trial
of bisoprolol in heart failure, but found only a non-significant
trend for EDV and ESV reduction over 12 months.39
Carvedilol differs from conventional b1 selective compounds
such as metoprolol and bisoprolol in that at therapeutic doses
it blocks all three adrenergic receptors (b1, b2, and a1),
resulting in a more comprehensive adrenergic protection of
the failing heart.40 Furthermore, it reduces cardiac adrenergic
activity41 and prevents the b1 receptor upregulation which is
typically seen with b1 selective agents such as metoprolol.42
Because of its a1 blocking properties, carvedilol causes
moderate peripheral vasodilatation which results in less
myocardial depression, no reduction in cardiac output, and
no initial haemodynamic compromise (which is normally
observed with pure b blockers).43 44 Thus it may be tolerated
better than other agents.
Conclusions
Treatment of chronic stable heart failure with carvedilol
results in significant improvement in left ventricular volumes
and thereby in reversal of adverse left ventricular remodel-
ling. This may partially explain the benefits of carvedilol on
mortality and morbidity in patients with chronic heart
failure.
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doi: 10.1136/hrt.2003.029165Giant left main stem thrombus in a patient with acute coronary syndrome
A
72 year old woman presented with
troponin positive acute coronary syn-
drome and was transferred to a ter-
tiary centre a week later. Her admission ECG
showed minimal ST depression in V2–V6
(maximum 1 mm) with a sinus bradycardia
of 38 beats/min. There was resolution of
symptoms and ECG changes on optimised
medical treatment which included low
molecular weight heparin. Cardiac enzymes
were not raised throughout the admission.
Coronary angiography showed a giant
thrombus in the distal left main stem.
Ostial disease was present in the left anterior
descending, circumflex, and obtuse marginal
vessels. The right coronary artery was a non-
dominant vessel with moderate proximal
disease. Left ventricular angiography showed
only mild dysfunction. In view of the
precarious proximity of the coronary throm-
bus, she underwent urgent three vessel
coronary bypass grafting. She made an
uneventful recovery but had a dual chamber
pacemaker implantation before discharge
because of persistent sinus node disease.
This case illustrates that despite a giant
distal left main thrombus in a dominant
coronary system, the patient was relatively
stable on medical treatment and had no
significant myocardial damage. Percutaneous intervention was considered a high risk
procedure because of the increased risk of distal embolisation of the thrombus. Urgent bypass
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